SLCO6A1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of SLCO6A1. The page also collects GeneMedi's different modalities and formats products for SLCO6A1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the SLCO6A1 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Predicted to enable sodium-independent organic anion transmembrane transporter activity. Predicted to be involved in sodium-independent organic anion transport. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. Predicted to be integral component of plasma membrane. [provided by Alliance of Genome Resources, Apr 2022]
Target ID | GM-MP1682 |
Target Name | SLCO6A1 |
Gene ID | 133482,74441,707421,488885,101090988,615094,100073211 |
Gene Symbol and Synonyms | 4933404A18Rik,CT48,GST,OATP-I,OATP6A1,OATPY,SLCO6A1,Slco6c1 |
Uniprot Accession | Q86UG4 |
Uniprot Entry Name | SO6A1_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000205359 |
Target Classification | N/A |
Pre-made anti-SLCO6A1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-SLCO6A1 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-SLCO6A1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-SLCO6A1 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody | Detail |
Multi-species SO6A1/ SLCO6A1/ CT48 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SLCO6A1 VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
SLCO6A1 VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |